

CLINICAL TRIAL

NCT03746522

Retinal RED
Pediatric RED



Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

Rare Eye Disease concerned by the trial :
Bardet-Biedl syndrome, Alström syndrome

Status of the trial : Active, not recruiting
Orphan drug recognition : N/A

Inclusion criteria : [Click here to see detailed criteria](#)

Exclusion criteria : [Click here to see detailed criteria](#)



Inclusion
opening date : 17/02/2020



Inclusion closing
date (previsional) : 21/03/2020

Children



Adults



Within ERN-EYE members



Principal location of the trial :
CARGO, Strasbourg University Hospital
1 Place de l'Hôpital - Bâtiment 2
67 091 Strasbourg cedex
France

[Contact details](#)




Principal investigator name :
Pr Hélène Dollfus



Other investigators :
Karine KLEMENT
**Sorbonne University Pitié-Salpêtrière AP-HP,
Paris, France**

Funder type : Industry



[More informations](#)